
FTC News


Facebook Agrees to Pay Record $5B to Settle Privacy Violation Claims
Facebook Inc. agreed to pay a record $5 billion to resolve a U.S. investigation into years of privacy violations, a settlement that increases the board of directors' responsibility for protecting ...
FTC Pursues Antitrust Suit Against Surescripts, Alleging Electronic Prescription Monopoly
The U.S. Federal Trade Commission filed an antitrust lawsuit against the health information network Surescripts on Wednesday, accusing them of using illegal means to maintain monopolies over two ...
Uber Agrees to Fork Over $20M to Settle FTC Suit Over Driver Pay
Uber Technologies Inc. agreed to pay $20 million to settle a U.S. Federal Trade Commission lawsuit over driver compensation claims and its auto leasing program. The FTC sued the San Francisco-based ...
ACE/Chubb Merger Plan Clears Federal Antitrust Regulatory Hurdle
ACE's planned $28 billion acquisition of Chubb cleared a major milestone necessary to meet a hoped-for completion of the deal in the 2016 first quarter. Specifically, the U.S. Federal Trade ...
Bayer Prevails in FTC Dietary Supplement Contempt Case
Bayer AG prevailed in a lawsuit filed by the U.S. Federal Trade Commission that accused the drugmaker's U.S. unit of making unsubstantiated claims about a dietary supplement marketed to promote ...
Court Ruling: FTC Has Authority to Regulate Corporate Cyber Security
A U.S. appeals court said the Federal Trade Commission has authority to regulate corporate cyber security, and may pursue a lawsuit accusing hotel operator Wyndham Worldwide Corp of failing to ...
U.S. Regulator Tells Web Search Firms To Label Ads Better
U.S. regulators warned leading Internet firms including Google Inc. to better identify paid ads in search results, particularly as new technology such as mobile services and voice-based online ...
Supreme Court Says FTC Can Sue Over Deals That Delay Generic Drug Sales
The U.S. Supreme Court ruled on Monday regulators can challenge deals between brand-name drug companies and generic rivals that delay cheaper medicines from going on sale, which regulators say ...